Ontario Institute for Cancer Research

Last updated
Ontario Institute for Cancer Research
Established2005
Research typeCancer
Field of research
 Genomics, Bioinformatics, Drug Discovery, Imaging, Cancer Stem Cells, Immuno- and Bio-therapies, Clinical Trials, Health Services Research,
President Dr. Laszlo Radvanyi
Staff 300+
Address MaRS Centre, 661 University Avenue, Suite 510
Location Toronto, Ontario, Canada
Website www.oicr.on.ca

The Ontario Institute for Cancer Research (OICR) is a not-for-profit organization based in Toronto, Ontario, Canada that focuses on research into the prevention, early detection, diagnosis and treatment of cancer. [1] OICR intends to make Ontario more effective in knowledge transfer and commercialization while maximizing the health and economic benefits of research findings for the people of Ontario. [2] OICR was launched in 2005 by the Government of Ontario, which provides funding through the Ministry of Colleges and Universities. The Institute employs more than 300 people at its research hub at the MaRS Centre in downtown Toronto and funds more than 1,900 scientific staff at hospital-based research institutes and universities around the province. In 2018 it was the highest funder of cancer research in Canada. [3]

Contents

History

Ontario Cancer Research Network

OICR’s predecessor organization was the Ontario Cancer Research Network (OCRN), a not-for-profit corporation established by the Government of Ontario in November 2001 to increase translational research related to the development of new cancer therapies. OCRN’s four main program areas were: the Ontario Tumour Bank, Clinical Trials Programs, the Ontario Cancer Research Ethics Board and the Cancer Research Fund. The organization was headed by Robert A. Phillips.

Ontario Institute for Cancer Research

In May 2005 the Government of Ontario announced its intent to launch a new cancer research institute in the province. OCRN was asked to evolve into the new institute, which would later be named OICR. OICR was formally launched by Ontario Premier Dalton McGuinty in December 2005. [4] OICR was designed to continue OCRN’s translational research programs while building new research capacity in the province. [2] Thomas J. Hudson was appointed President and Scientific Director of OICR in June 2006 [5] and Robert A. Phillips was appointed Deputy Director. Hudson consulted with the Ontario cancer research community and external experts to develop a strategic research plan for the Institute in 2006. In February 2007 the completed strategic plan was approved by the Ministry of Research and Innovation. Laszlo Radvanyi was appointed President and Scientific Director of OICR in May 2018. [6] The current strategic plan is updated to reflect patient partnership as a priority. [7] [8] OICR is funded by the Ontario Ministry of Colleges and Universities.

Cancer Research

Resources

OICR hosts a number of cancer research resources, including the Ontario Cancer Research Ethics Board (OCREB); the Ontario Tumor Bank (OTB); the Ontario Health Study, the Ontario arm of the CanPath longitudinal study - the largest such study in Canada; and the Canadian Cancer Clinical Trials Network (CCTG).

Commercialization

As part of its mandate to bring economic benefit to Ontario through cancer research, OICR has a partner organization that focuses on commercialization, FACIT [9] . FACIT provides seed funding to Ontario-based cancer research companies and helps them attract other investors and bring products to market. It claims to have attracted $1.6 billion in investment from $50 million in funding [10] . Notable investments includes Fusion Pharmaceuticals, which was purchased by AstraZeneca for up to $2.4 billion in 2024, and Turnstone Biologics, which is listed on the Nasdaq stock exchange. [11] [12] It hosts an annual pitch competition called Falcons' Fortunes, in the style of the Dragons' Den television series.

Notable people

John Edgar Dick - Cancer stem cell researcher

Lincoln Stein - Bioinformatics and Computational biology researcher

Related Research Articles

Health Canada is the department of the Government of Canada responsible for national health policy. The department itself is also responsible for numerous federal health-related agencies, including the Canadian Food Inspection Agency (CFIA) and the Public Health Agency of Canada (PHAC), among others. These organizations help to ensure compliance with federal law in a variety of healthcare, agricultural, and pharmaceutical activities. This responsibility also involves extensive collaboration with various other federal- and provincial-level organizations in order to ensure the safety of food, health, and pharmaceutical products—including the regulation of health research and pharmaceutical manufacturing/testing facilities.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

The Ministry of Research, Innovation and Science was a government ministry of the Province of Ontario. Founded in 2005, the ministry became part of the Ministry of Economic Development and Innovation in 2011. It intermittently became a separate ministry in again from 2013 until 2018, when it became part of the Ministry of Economic Development, Job Creation and Trade.

MaRS Discovery District is a not-for-profit corporation founded in Toronto, Ontario, Canada in 2000. Its stated goal is to commercialize publicly funded medical research and other technologies with the help of local private enterprises and as such is a public-private partnership. As part of its mission MaRS says, "MaRS helps create successful global businesses from Canada's science, technology and social innovation." As of 2014, startup companies emerging from MaRS had created more than 4,000 jobs, and in the period of 2011 to 2014 had raised over $750 million in capital investments.

<span class="mw-page-title-main">Cambridge Biomedical Campus</span> Science park in Cambridge, UK

The Cambridge Biomedical Campus is the largest centre of medical research and health science in Europe. The site is located at the southern end of Hills Road in Cambridge, England.

<span class="mw-page-title-main">Cediranib</span> Chemical compound

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

Expenditures by federal and provincial organizations on scientific research and development accounted for about 10% of all such spending in Canada in 2006. These organizations are active in natural and social science research, engineering research, industrial research and medical research.

Expenditures by Canadian universities on scientific research and development accounted for about 40% of all spending on scientific research and development in Canada in 2006.

Expenditures by Canadian corporations on research and development accounted for about 50% of all spending on scientific research and development in Canada in 2007.

Sir Menelaos (Mene) Nicolas Pangalos is a British neuroscientist of Greek descent.

The National Health Council (NHC) is a nonprofit association of health organizations.

The Stem Cell Network (SCN) is a Canadian non-profit that supports stem cell and regenerative medicine research, teaches the next generation of highly qualified personal, and delivers outreach activities across Canada. The Network has been supported by the Government of Canada, since inception in 2001. SCN has catalyzed 25 clinical trials, 21 start-up companies, incubated several international and Canadian research networks and organizations, and established the Till & McCulloch Meetings, Canada's foremost stem cell research event.

Alan Bernstein is Professor Emeritus at the University of Toronto and President Emeritus of CIFAR, where he served as President and CEO from 2012 to 2022. A Distinguished Fellow at the Munk School of Global Affairs and Public Policy, he is also a Fellow and Member of the Standing Committee for Science Planning at the International Science Council (2022-2025). Bernstein is recognized as a leader in health research, science policy, mentorship and organizational leadership.

<span class="mw-page-title-main">LifeArc</span>

LifeArc is a British life science medical research charity. It was established in 2000 as MRC Technology to translate the work of UK Medical Research Council (MRC) research scientists.

<span class="mw-page-title-main">Stephen Jackson (biologist)</span> British biologist

Sir Stephen Philip Jackson, FRS, FMedSci is the Frederick James Quick Professor of Biology. He is a senior group leader at the Cancer Research UK Cambridge Institute and associate group leader at the Gurdon Institute, University of Cambridge.

Gordon B. Mills is the Wayne and Julie Drinkward Endowed Chair in Precision Oncology, Director of Precision Oncology, Director of SMMART Trials and Professor in Cell, Development and Cancer Biology in the Knight Cancer Institute at Oregon Health & Science University.

Christine Allen is a Canadian professor and the first associate vice-president and vice-provost for strategic initiatives at the University of Toronto. She served formerly as interim dean of the university's Leslie Dan Faculty of Pharmacy. She is co-founder of Nanovista, a company focused on imaging of tumors. She also works as the associate editor of Molecular Pharmaceutics.

The Global Alliance for Genomics and Health (GA4GH) is an international consortium that is developing standards for responsibly collecting, storing, analyzing, and sharing genomic data in order to enable an "internet of genomics". GA4GH was founded in 2013.

Peter Jüni is a Swiss physician, general internist, and epidemiologist based in England.

<span class="mw-page-title-main">Dmitry Bandura</span> Canadian Scientist, Co-inventor of Mass Cytometry technology

Dmitry Bandura is a Soviet-born Canadian scientist, notable for being one of the co-inventors of the Mass cytometry technology. Bandura co-founded DVS Sciences in 2004 along with Drs Vladimir Baranov, Scott D. Tanner, and Olga Ornatsky.

References

  1. ↑ OICR website
  2. 1 2 Ministry of Economic Development and Innovation
  3. ↑ Canadian Cancer Research Alliance
  4. ↑ FINDING NEW AND BETTER WAYS TO FIGHT CANCER - DECEMBER 2, 2005 (News Release)
  5. ↑ Has Ontario found 'THE NEW MESSIAH' of cancer research? Globe and Mail, November 13, 2006
  6. ↑ OICR names Dr. Laszlo Radvanyi as new President and Scientific Director OICR, March 28, 2018
  7. ↑ Research Strategy Overview, 2022
  8. ↑ Cancer solved together OICR Strategic Plan 2021-2026, 2021
  9. ↑ "FACIT - Cancer Breakthroughs Realized". FACIT. Retrieved 2024-04-09.
  10. ↑ "About Us". FACIT. Retrieved 2024-04-09.
  11. ↑ "FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca". FACIT. 2024-03-20. Retrieved 2024-04-09.
  12. ↑ "FACIT founded Turnstone Biologics debuts on Nasdaq market". FACIT. 2023-07-21. Retrieved 2024-04-09.

43°39′35.29″N79°23′20.08″W / 43.6598028°N 79.3889111°W / 43.6598028; -79.3889111

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.